The U of M licensed its eye scanning system for early Alzheimer's detection to RetiSpec, a medical imaging company.
RetiSpec will get exclusive access to the system, with the idea that combining the technology with RetiSpec’s own machine learning program will advance the development.
The imaging system—developed by researchers for the university’s College of Pharmacy Center for Drug Design—scans a patient’s eye to detect small quantities of a protein called beta amyloid.
What makes the system unique is that it can do this before the protein collects into large enough clusters to form plaques in the brain, the standard biological sign of Alzheimer’s progression.
The full story was published in October, 2018, in Twin Cities Business.